Molecular biology exploration and targeted therapy strategy of Ameloblastoma

Lu, Yiwen; Zhang, Xudong; Li, Xiangjun

doi:10.1016/j.archoralbio.2022.105454

Cited by 7 publications

(8 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecularly targeted therapy research is focused on BRAF mutations, as 63% to 82% of AM patients and 38% of AMCa patients have BRAF V600E mutations ( 9 , 20 – 24 ).And most of them are located in the mandible and are sensitive to targeted drugs such as vemurafenib. BRAF-V600E mutations have also been found to be associated with aggressive behavior in AMCa, which can be accurately diagnosed by immunohistochemistry, which can be used to assess prognosis and select treatment ( 12 , 15 , 24 – 27 ). A small number of studies have found that SMO-mutated AM are predominantly located in the maxilla, however, more clinical studies are needed to overcome resistance to targeted drugs and reduce adverse effects ( 12 , 24 , 28 ).…”

Section: Discussionmentioning

confidence: 99%

“…BRAF-V600E mutations have also been found to be associated with aggressive behavior in AMCa, which can be accurately diagnosed by immunohistochemistry, which can be used to assess prognosis and select treatment ( 12 , 15 , 24 – 27 ). A small number of studies have found that SMO-mutated AM are predominantly located in the maxilla, however, more clinical studies are needed to overcome resistance to targeted drugs and reduce adverse effects ( 12 , 24 , 28 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Malignant transformation of primary ameloblastoma of skull: case report and review of current literature

Xu,

Tan,

2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundSince 1964, there has been a scarcity of reported cases of primary ameloblastoma (AM) or ameloblastic carcinoma (AMCa) of the skull. The clinical presentation and distinctive features of this uncommon condition at specific anatomical sites remain unclear. We report a case of malignant transformation of a primary AM of the skull situated in the frontal-temporal-parietal region and highlight its similarities to other cases reported in the literature.Clinical presentationA 53-year-old female patient presented with a 20-day history of headaches and bilateral lower limb weakness for 10 days. Physical examination revealed slow and unsteady gait. An occupying lesion was observed in the right frontal-temporal-parietal region of the skull on the Cranial imaging. A right cranial bone tumor margin expansion resection was performed. The patient’s motor functions recovered normally after surgery. Postoperative imaging examinations showed10 tumor resection. Follow-up imaging examinations showed tumor recurrence. The patient underwent resection of the recurrent tumor. Postoperative pathological analysis revealed malignant transformation of the AM.Follow-up imaging examinations showed tumor recurrence again. The patient was admitted for stereotactic radiotherapy. Follow-up imaging examinations demonstrated no evidence of tumor recurrence and subsequent chest CT revealed no signs of metastasis.ConclusionPrimary AM or AMCa of the skull is increasingly being described in the literature, but detailed reports on the malignant transformation of primary AM of the skull are lacking. The pathogenesis of this condition remains unclear. Aggressive treatment and close follow-up may be crucial for preventing disease recurrence and malignant transformation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Malignant transformation of primary ameloblastoma of skull: case report and review of current literature

Xu,

Tan,

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…[9][10][11] Recent studies have provided a breakthrough in understanding the genetic mutations associated with ameloblastoma and in the potential use of molecular-targeted therapies as a neoadjuvant treatment. 12 Except for Ki-67 and p53, whose association with ameloblastoma has been confirmed, various protein markers-such as cyclooxygenase-2, AMFR, collagen IV, VEGF, and toll-like receptor 2-were proved to be associated with tumour neoplasia and the recurrence of local infiltration. The utility of proteomics has been widely explored in the field of dentistry, in addition to the comprehensive and in-depth development of other oncology areas; it has been used in the study of dental caries, 13 periodontitis, 14 and oral cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Recent studies have provided a breakthrough in understanding the genetic mutations associated with ameloblastoma and in the potential use of molecular‐targeted therapies as a neoadjuvant treatment 12 . Except for Ki‐67 and p53, whose association with ameloblastoma has been confirmed, various protein markers—such as cyclooxygenase‐2, AMFR, collagen IV, VEGF, and toll‐like receptor 2—were proved to be associated with tumour neoplasia and the recurrence of local infiltration.…”

Section: Introductionmentioning

confidence: 99%

A proteomics study to explore differential proteins associated with the pathogenesis of ameloblastoma

Cui

Xiao

et al. 2023

J Oral Pathology Medicine

Self Cite

View full text Add to dashboard Cite

Background Reports on the proteomic studies of ameloblastoma and other common odontogenic lesions are limited. We thus explored the differential proteins among ameloblastoma, odontogenic keratocyst, dentigerous cyst, and normal gingival tissue using proteomics and identified hub proteins involved in the local aggressiveness and recurrence of ameloblastoma. Methods Samples were obtained from 14 patients with ameloblastoma, 6 with odontogenic keratocyst, 9 with a dentigerous cyst, and 5 with normal gingival tissue. Proteins were then extracted, purified, quantified, and analysed using Easy‐nLC chromatography and mass spectrometry. Further functional annotation and enrichment analyses were performed using Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes on the target protein collection. Protein clustering and protein–protein interaction network analyses were used to screen the hub proteins. Proteins with significant interactions were screened according to their degree index. These results were verified by immunohistochemical staining. Proteins meeting the screening criteria of expression difference ploidy >1.2‐fold (upregulation and downregulation) and p < 0.05 were considered differential proteins. Results In ameloblastoma, 808 differential proteins were upregulated and 505 were downregulated compared with those in odontogenic keratocyst; 309 were upregulated and 453 were downregulated compared with those in dentigerous cyst; and 2210 were upregulated and 829 were downregulated compared with those in normal gingival tissue. The three groups of differential proteins were associated with cellular exosomes, antigen binding, complement activation, human papillomavirus infection, focal adhesion, cell adhesion molecules, and metabolic pathways. Conclusion CDH3 is associated with the local aggressiveness and recurrence of ameloblastoma and is a potential therapeutic target.

show abstract

“…Non-surgical management of ameloblastoma consists of radiotherapy, chemotherapy, or target therapy and it is addressed to patients medically unstable for surgery or to treat ameloblastic carcinoma and recurrent ameloblastoma after multiple postsurgical recurrences [ 4 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Mandibular Reconstruction after Resection of Ameloblastoma by Custom-Made CAD/CAM Mandibular Titanium Prosthesis: Two Case Reports, Finite Element Analysis and Discussion of the Technique

et al. 2023

View full text Add to dashboard Cite

Virtual surgical planning for CAD/CAM mandibular reconstruction by titanium prosthesis was recently reported for resected cases. Even if some advantages are evident, difficulties that may arise for TMJ function after reconstruction originate from prosthesis contamination through oral mucosa dehiscence. In these two cases reported of mandibular reconstruction after resection of ameloblastoma by custom-made CAD/CAM titanium prosthesis, the procedures were aimed to preserve the TMJ glenoid cavity and articular disc avoiding functional problems for hemi-mandibular resections that included the condyle (as in case #1) or with condylar preservation (as in case #2) and avoiding intraoral incisions in both cases. The entire surgical planning and prosthetic fabrication were explained with specifications and the sequence of the surgical procedure. Finite elements analysis (FEA) was performed to check the force distribution and efficacy of the prosthetic device (case 1 with hemi-mandibular resection and rehabilitation). Although successful in these two cases, surgical reconstruction of the mandibular defect after resection by a CAD-CAM custom-made prosthesis still shows some drawbacks and failure risks. Several advantages of this technique and the surgical success in these two cases were presented, but limitations and side effects must be considered when cases are selected.

show abstract

Molecular biology exploration and targeted therapy strategy of Ameloblastoma

Cited by 7 publications

References 142 publications

Malignant transformation of primary ameloblastoma of skull: case report and review of current literature

Malignant transformation of primary ameloblastoma of skull: case report and review of current literature

A proteomics study to explore differential proteins associated with the pathogenesis of ameloblastoma

Mandibular Reconstruction after Resection of Ameloblastoma by Custom-Made CAD/CAM Mandibular Titanium Prosthesis: Two Case Reports, Finite Element Analysis and Discussion of the Technique

Contact Info

Product

Resources

About